NCT03936153 2025-04-10Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Xynomic Pharmaceuticals, Inc.Phase 2 Recruiting170 enrolled